Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Palbociclib

    Virtual Booth

    Contact Supplier

    Palbociclib

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Palbociclib

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Palbociclib [USAN]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,858Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Ibrance

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 4,961

    2018 Revenue in Millions : 4,118

    Growth (%) : 20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 5,392

    2019 Revenue in Millions : 4,961

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 5,437

    2020 Revenue in Millions : 5,392

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 5,120

    2021 Revenue in Millions : 5,437

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 4,753

    2022 Revenue in Millions : 5,120

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 4,367

    2023 Revenue in Millions : 4,753

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 0

    2014 Revenue in Millions : 723

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 2,135

    2015 Revenue in Millions : 723

    Growth (%) : 195

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer Inc.

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 3,126

    2016 Revenue in Millions : 2,136

    Growth (%) : 46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Ibrance

    Palbociclib

    arrow
    VMX
    Not Confirmed

    Brand Name : Ibrance

    U.S.A
    arrow
    VMX
    Not Confirmed

    Pfizer

    Palbociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 4,118

    2017 Revenue in Millions : 3,126

    Growth (%) : 32%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.